CHINA – Canton Biologics, a Guangzhou, China-based molecule biopharmaceutical CDMO, raised over 300M Yuan in Series C funding.
The round was led by SDIC Venture Capital, with participation from Guangdong Technology Financial Group, Taipu Life Science Investment, and Chnin Financial. The company intends to use the funds to expand its R&D in novel biotechnologies, scale commercial production capabilities, and expand its global strategic presence.Founded in Guangzhou in 2016 by Dr. Xiao Shen, Founder and CEO, Canton Biologics offers end-to-end services from biopharmaceutical CMC development to commercial production and global clinical supply. The company, which has high-yield cell line development, complex protein expression, and international manufacturing capabilities, has also made significant advancements in the lgM molecule expression platform, expression host cells, high-density cell culture, new formulations, and analytical methodologies. 18/09/2023
